Diadem Biotherapeutics

Diadem Biotherapeutics is a private, pre-clinical stage biotech leveraging engineered extracellular vesicles as a novel drug delivery and cell communication modality. The company's core technology, the DECOSTAR™ platform, bioengineers EVs to precisely activate or repress immune receptors, aiming to access validated immunotherapy targets for oncology and autoimmunity. Founded by a team of bioengineers and drug developers, Diadem is backed by venture capital and is developing a pipeline of potential first-in-class therapeutics, though it remains pre-revenue and in the early research phase.

DECOSTAR™ platform for engineering extracellular vesicles (EVs) to present immune receptor ligands in a multivalent fashion, mimicking cell-to-cell contact to achieve potent agonist or antagonist signaling for immune modulation.

Diadem competes in the rapidly evolving fields of extracellular vesicle therapeutics and immune modulation. Competitors range from other EV-focused biotechs (e.g., Codiak BioSciences, Evox Therapeutics) to large pharma companies developing antibody and cell-based immunotherapies. Success will depend on demonstrating clear pharmacological advantages over these established and emerging modalities.